Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PBH Stock Forecast 2026-2027
$50.60
Current Price
$2.24B
Market Cap
Buy 5
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to PBH Price Targets
+48.2%
To High Target of $75.00
+38.3%
To Median Target of $70.00
-1.2%
To Low Target of $50.00
PBH Price Momentum
+3.5%
1 Week Change
+9.7%
1 Month Change
-32.7%
1 Year Change
-18.0%
Year-to-Date Change
-34.7%
From 52W High of $77.45
+18.7%
From 52W Low of $42.62
📊 TOP ANALYST CALLS
Did PBH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Prestige Healthcare is one of their latest high-conviction picks.
Latest PBH Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, PBH has a bullish consensus with a median price target of $70.00 (ranging from $50.00 to $75.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $50.60, the median forecast implies a 38.3% upside. This outlook is supported by 5 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PBH Analyst Ratings
5
Buy
2
Hold
0
Sell
PBH Price Target Range
Low
$50.00
Average
$70.00
High
$75.00
Current: $50.60
Latest PBH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PBH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2026 | Canaccord Genuity | Susan Anderson | Buy | Maintains | $72.00 |
| May 14, 2026 | Oppenheimer | Rupesh Parikh | Perform | Downgrade | $N/A |
| May 7, 2026 | Oppenheimer | Outperform | Maintains | $N/A | |
| Feb 2, 2026 | Jefferies | Hold | Maintains | $N/A | |
| Nov 7, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Oct 27, 2025 | Jefferies | Hold | Maintains | $N/A | |
| Oct 21, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Aug 8, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 21, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Feb 13, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Feb 7, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Feb 7, 2025 | DA Davidson | Buy | Maintains | $N/A | |
| Nov 11, 2024 | DA Davidson | Buy | Maintains | $N/A | |
| Sep 24, 2024 | Jefferies | Stephanie Wissink | Hold | Assumes | $76.00 |
| Aug 28, 2024 | DA Davidson | Buy | Maintains | $N/A | |
| Aug 9, 2024 | DA Davidson | Buy | Maintains | $N/A | |
| Aug 9, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Jun 21, 2024 | DA Davidson | Buy | Upgrade | $N/A | |
| May 21, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| May 16, 2024 | DA Davidson | Neutral | Maintains | $N/A |
Prestige Consumer Healthcare Inc. (PBH) Competitors
The following stocks are similar to Prestige Healthcare based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PBH
Prestige Healthcare
mkt cap
2.32B
Prestige Consumer Healthcare Inc. (PBH) Financial Data
Prestige Consumer Healthcare Inc. has a market capitalization of $2.24B with a P/E ratio of 12.1x. The company generates $1.09B in trailing twelve-month revenue with a 17.5% profit margin.
Revenue growth is -5.0% quarter-over-quarter, while maintaining an operating margin of +26.8% and return on equity of +10.2%.
Valuation Metrics
Market Cap
$2.24B
Enterprise Value
$3.29B
P/E Ratio
12.1x
PEG Ratio
0.9x
Price/Sales
2.1x
Growth & Margins
Revenue Growth (YoY)
-5.0%
Gross Margin
+51.9%
Operating Margin
+26.8%
Net Margin
+17.5%
EPS Growth
+7.6%
Financial Health
Cash/Price Ratio
+2.7%
Current Ratio
3.6x
Debt/Equity
55.4x
ROE
+10.2%
ROA
+5.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Prestige Consumer Healthcare Inc. (PBH) Business Model
About Prestige Consumer Healthcare Inc.
What They Do
Produces and distributes over-the-counter healthcare products.
Business Model
The company operates in the consumer staples sector, generating revenue by selling a wide range of over-the-counter healthcare and household cleaning products. It markets well-known brands across various categories, such as analgesics and oral care, through multiple distribution channels including drug stores, grocery outlets, and e-commerce platforms.
Additional Information
Prestige Consumer Healthcare Inc. addresses consumer demands for accessible healthcare solutions, establishing itself as a significant player in the wellness and personal care markets. Its diverse product portfolio allows it to cater to a wide audience, enhancing its market presence and potential for growth.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
890
CEO
Mr. Ronald M. Lombardi CPA
Country
United States
IPO Year
2005
Website
www.prestigebrands.comPrestige Consumer Healthcare Inc. (PBH) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Is the Options Market Predicting a Spike in Prestige Consumer Healthcare Stock?
Investors need to pay close attention to PBH stock based on the movements in the options market lately.
Jul 06, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Prestige Consumer Healthcare Inc. (NYSE:PBH) has completed its acquisition of LaCorium Health and priced a $400 million senior notes offering. Q1 fiscal 2027 results will be reported on August 6, 2026.
Why It Matters
Prestige's acquisition of LaCorium and the $400 million senior notes offering indicate growth potential and financial strategies that could impact stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors should monitor PBH stock due to recent activity in the options market, indicating potential changes in market sentiment.
Why It Matters
Increased activity in the options market for PBH stock suggests heightened investor interest or volatility expectations, potentially signaling future price movements.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Prestige Consumer Healthcare Inc. plans to issue up to $400 million in new senior unsecured notes due 2034 through its subsidiary Prestige Brands, subject to market conditions.
Why It Matters
Prestige Consumer Healthcare's plan to issue $400 million in senior notes signals potential funding for growth or debt refinancing, impacting liquidity, leverage, and overall financial health.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Prestige Consumer Healthcare (NYSE: PBH) shares dropped over 11% on May 14, 2026, due to revenue declines and production issues. A shareholder rights firm is investigating potential transparency and legal compliance.
Why It Matters
Prestige Consumer Healthcare's significant revenue decline and production issues have triggered an 11% share drop and a legal investigation, raising concerns about transparency and potential liabilities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Prestige Consumer Healthcare (NYSE: PBH) shares dropped over 11% on May 14, 2026, due to revenue declines and production issues. An investigation into potential transparency violations is underway.
Why It Matters
Prestige Consumer Healthcare's share price drop and revenue declines signal potential mismanagement and transparency issues, raising legal concerns that could further impact investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Prestige Consumer Healthcare Inc. (NYSE: PBH) has completed its acquisition of the Breathe Right® brand and other brands, as announced on June 15, 2026.
Why It Matters
The acquisition of Breathe Right® by Prestige Consumer Healthcare could enhance its product portfolio and revenue potential, impacting stock performance and market competitiveness.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PBH Stock
What is Prestige Consumer Healthcare Inc.'s (PBH) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, Prestige Consumer Healthcare Inc. (PBH) has a median price target of $70.00. The highest price target is $75.00 and the lowest is $50.00.
Is PBH stock a good investment in 2027?
According to current analyst ratings, PBH has 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $50.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PBH stock?
Wall Street analysts predict PBH stock could reach $70.00 in the next 12 months. This represents a 38.3% increase from the current price of $50.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Prestige Consumer Healthcare Inc.'s business model?
The company operates in the consumer staples sector, generating revenue by selling a wide range of over-the-counter healthcare and household cleaning products. It markets well-known brands across various categories, such as analgesics and oral care, through multiple distribution channels including drug stores, grocery outlets, and e-commerce platforms.
What is the highest forecasted price for PBH Prestige Consumer Healthcare Inc.?
The highest price target for PBH is $75.00 from at , which represents a 48.2% increase from the current price of $50.60.
What is the lowest forecasted price for PBH Prestige Consumer Healthcare Inc.?
The lowest price target for PBH is $50.00 from at , which represents a -1.2% decrease from the current price of $50.60.
What is the overall PBH consensus from analysts for Prestige Consumer Healthcare Inc.?
The overall analyst consensus for PBH is bullish. Out of 4 Wall Street analysts, 5 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $70.00.
How accurate are PBH stock price projections?
Stock price projections, including those for Prestige Consumer Healthcare Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 3:03 AM UTC